Literature DB >> 8634441

Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells.

M Urashima1, A Ogata, D Chauhan, M Hatziyanni, M B Vidriales, D A Dedera, R L Schlossman, K C Anderson.   

Abstract

Interleukin-6 (IL-6), a product of bone marrow stromal cells (BMSCs), is a growth factor for multiple myeloma (MM) cells. Transforming growth factor-beta1 (TGF-beta1) is also produced by BMSCs and can regulate IL-6 secretion by several tissues, including BMSCs. The present study was designed to characterize in vitro tumor growth regulation by TGF-beta1 in MM. Sorted CD38+CD45RA- MM cells secreted significantly more TGF-beta1 (8.2 +/- 2.0 ng/mL) than peripheral blood mononuclear cells (P < .001), splenic B cells (P < .001), and CD40 ligand (CD40L) pretreated B cells (P < .05). TGF-beta1 secretion by MM-BMMCs (3.8 +/- 0.9 ng/mL) was significantly greater than by N-BMMCs (1.2 +/- 0.1 ng/mL, P < .001). MM-BMSCs also secreted significantly more TGF-beta1 (6.6 +/- 2.5 ng/mL, n = 11) than N-BMSCs (4.4 +/- 0.6 ng/mL, P < .02, n = 10) and N-BMSC lines (3.9 +/- 0.2 ng/mL, P < .02, n = 6). TGF-beta1 secretion was correlated with IL-6 secretion in MM-BMSCs. Anti-TGF-beta1 monoclonal antibody both blocked IL-6 secretion by BMSCs and inhibited the increments in IL-6 secretion by BMSCs induced by MM cell adhesion. Moreover, exogenous TGF-beta1 upregulated IL-6 secretion by MM-BMSCs, normal BMSCs, and CD38+ CD45RA- MM cells, as well as tumor cell proliferation. This is in contrast to the inhibitory effect of TGF-beta1 on proliferation and Ig secretion of normal splenic B cells. Finally, retinoblastoma proteins (pRB) are constitutively phosphorylated in MM cells; TGF-beta1 either did not alter or increased pRB phosphorylation. pRB are dephosphorylated in splenic B cells and phosphorylated in CD40L triggered B cells in contrast to its effects on MM cells, TGF-beta1 decreased phosphorylation of pRB in CD40L treated B cells. These results suggest that TGF-beta1 is produced in MM by both tumor cells and BMSCs, with related tumore cell growth. Moreover, MM cell growth may be enhanced by resistance of tumor cells to the inhibitory effects of TGF-beta1 on normal B-cell proliferation and Ig secretion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8634441

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

1.  Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies.

Authors:  M A Frassanito; L Rao; M Moschetta; R Ria; L Di Marzo; A De Luisi; V Racanelli; I Catacchio; S Berardi; A Basile; E Menu; S Ruggieri; B Nico; D Ribatti; R Fumarulo; F Dammacco; K Vanderkerken; A Vacca
Journal:  Leukemia       Date:  2013-09-02       Impact factor: 11.528

2.  Transforming growth factor-beta and multidrug resistance in chronic lymphocytic leukemia.

Authors:  W R Friedenberg; S A Salzman; S M Phan; J K Burmester
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

Review 3.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

4.  Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.

Authors:  M A Frassanito; K De Veirman; V Desantis; L Di Marzo; D Vergara; S Ruggieri; T Annese; B Nico; E Menu; I Catacchio; R Ria; V Racanelli; M Maffia; E Angelucci; D Derudas; R Fumarulo; F Dammacco; D Ribatti; K Vanderkerken; A Vacca
Journal:  Leukemia       Date:  2015-10-21       Impact factor: 11.528

5.  Transforming growth factor-{beta}1 modulates responses of CD34+ cord blood cells to stromal cell-derived factor-1/CXCL12.

Authors:  Sunanda Basu; Hal E Broxmeyer
Journal:  Blood       Date:  2005-03-29       Impact factor: 22.113

Review 6.  Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease.

Authors:  Joanne E Murphy-Ullrich; Mark J Suto
Journal:  Matrix Biol       Date:  2017-12-27       Impact factor: 11.583

Review 7.  Preclinical studies of novel targeted therapies.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

8.  The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.

Authors:  Robert O'Connor; Melissa G Ooi; Justine Meiller; Jana Jakubikova; Steffen Klippel; Jake Delmore; Paul Richardson; Kenneth Anderson; Martin Clynes; Constantine S Mitsiades; Peter O'Gorman
Journal:  Cancer Chemother Pharmacol       Date:  2013-04-16       Impact factor: 3.333

Review 9.  Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.

Authors:  H Quach; D Ritchie; A K Stewart; P Neeson; S Harrison; M J Smyth; H M Prince
Journal:  Leukemia       Date:  2009-11-12       Impact factor: 11.528

Review 10.  Role of transforming growth factor-beta in hematologic malignancies.

Authors:  Mei Dong; Gerard C Blobe
Journal:  Blood       Date:  2006-02-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.